Home > Boards > Canadian > Cannabis >

Abattis Bioceuticals Corp. (ATTBF)

Add ATTBF Price Alert      Hide Sticky   Hide Intro
Moderator: Goodbuddy4863, GreenBrickRoad
Search This Board: 
Last Post: 3/23/2018 2:16:38 AM - Followers: 367 - Board type: Free - Posts Today: 0

Welcome to Abattis Bioceuticals Corp.

Abattis Confirms Breakthrough Extraction Technology Capabilities


ATTBF – Abattis looks to become a leader in extraction with proprietary Raybot extraction technology Raybot has repurposed its industrial Preparative Chromatography Separation System, previously used in Tobacco, Pharma and Natural Food industries, specifically for implementation in the Cannabis industry.
Let us explain...

Notable Products Created with Raybot Technology:
Resveratrol | 98% purity
5-HTP | 99% purity
Ginkgo Biloba Extract | 24% purity
Inositol | 99% purity
Co-Enzyme Q10 | 98.5% purity


Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets, some of which will contain cannabinoid compounds. Abattis develops and is in the process of commercializing natural health products that target ailments and satisfy important market needs. Abattis is conducting ongoing research and development to create plant-based intellectual property and ingredients. Current areas of focus are growth through acquisition and business development and cash flow through commercialization of existing assets.

Biocell Labs Inc. - is a wholly-owned subsidiary focused on providing standardized pharmaceutical-grade products. Currently, the company has 13 proprietary formulations for out-licensing to cosmetic, nutraceutical and pharmaceutical companies.

Northern Vine Labs™, a subsidiary of Abattis, seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada, with existing cannabis processing, testing, and packaging facility located in Langley, British Columbia. In addition to these services, the company supports its operations by providing analytical services for Licensed Producers.

North American Bioextracts – is a retail distribution arm operating in Canada and Washington State focusing on cannabis, cannabis derivatives, and ancillary products like vaporizers. The company aims to use its proprietary extraction technologies to develop customized THC extract oils and CBD extract oils, as well as customized vaporizer flavors to enhance the end user’s experience.

Vergence Sales & Marketing Group – creates botanical formulations, medical marijuana and specialized health products for safe and effective solutions to pain caused by inflammation and mental ailments common to "modern lifestyle".

Through our divisions Biocell Labs Inc. and Vergence Sales & Marketing Group, we develop and license natural health products and have future plans to expand into the nutraceutical, pharmaceutical and cosmetic markets. The Company has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding natural health product market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions.

Within our other divisions Northern Vine, North American Bioextracts and Biocube we have capabilities that support the production and extraction of botanical ingredients for our products; one of which includes cannabis.

For more information, visit the Company's website at: Executive Overview (PDF download file)

Our investors are forward thinkers in the emerging bioceutical and medical marijuana markets. We are a specialty, vertically-integrated biotechnology company that aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. From patented and proprietary formulations, extraction and processing methods, Abattis consistently seeks opportunities to participate in varied markets all connected by a common global purpose and customer base: seeking health through natural products.
Abattis is uniquely positioned to fully exploit the growing trend toward marijuana legalization in the United States and medicinal use in Canada as licensed and international jurisdictions.

“Health Canada estimates that the emerging medical marijuana market to be in excess of $1 billion.
Stephen Easton, an SFU Economist, estimated that nationally the Cannabis industry generates approximately $19 to $21 billion”

We develop and license natural health products with unique botanical blends, CBD and proprietary ingredients. These infused food and beverage brands are designed for wellness nutraceuticals, medical foods & botanical drugs market with future plans to expand into the pharmaceutical and cosmetic markets.

Canada’s cannabis industry is expected to surpass $22 billion in size over the coming years, according to Deloitte, with over 140,000 registered medical marijuana patients today. With about 40 licensed producers under the ACMPR, the industry is expected to see a shortfall in supply given the 205% compound annual growth rate in registered patients since June of 2014 along with the near-term plans to legalize marijuana for recreational use.

Northern Vine Labs™ is getting ready for our launch.

Visit our website and join our community for updates and educational information.


Northern Vine Labs™ are now on Health Canada list for licensed dealers!
The following link shows a list of laboratories that have a current Dealers Licence under the Narcotic Control Regulations and who are licensed to conduct activities with cannabis:

Northern Vine Labs™, a subsidiary of Abattis, seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada. The ability to legally work with Cannabis remains rare and highly specialized. Northern Vine Labs™ Controlled Substance License enables proprietary methods and services to be offered to currentlicensed producers within Canada’s existing Federal regulatory structure. It also offers Northern Vine Labs™ customers, including Abattis, the ability to formulate and develop new products containing cannabinoid ingredients in advance of the end to prohibition.


In partnership with the BC Institute of Technology (BCIT), Northern Vine Labs™ has been working to develop new and improved methods for the analysis of cannabis. This work is expected to be published by BCIT positioning NV Labs as the industry expert in analytical services which are substantially faster and more reliable than any other in Canada. Utilizing these proprietary methods, Northern Vine Labs will offer for sale its analytical reference standards enabling market participants to check quality and metrological traceability of products, to validate analytical measurement methods, and/or to support the proper calibration of instruments.
Northern Vine Labs™ operations under the CSL will include:
1. Analytical Services
2. Research and Development Services
3. Extraction to Support Analysis and R&D?
In future, NV Labs anticipates the opportunity to amend its license to include:
4. Extraction service for sale of extracted ingredients
5. Importation/Exportation

Analytical Services
Potency Testing Determining composition and concentration of various cannabinoid compounds
Moisture Analysis and Foreign Matter Testing
Microbiological Testing
Ensuring the safety of products by testing for levels of mold and bacteria.

The Cannabis Trade Alliance of Canada, which represents producers, said the new regime should provide for mandatory testing: 

“Mandatory laboratory testing of all cannabis products (potency and contaminants) – a critical step in the seed-to-sale process when considering public health, and should be the main objective in the legalized framework.”


Vergence Visionary Bioceuticals, a subsidiary of Abattis, is a team of nutraceutical marketing and brand specialists focused on innovative health products to penetrate the fast growing market for natural, safe and effective solutions to two of society’s unresolved and ubiquitous health issues: Pain caused by inflammation and mental ailments common to our modern lifestyle. Vergence is the exclusive exporter of 99.6%, organic and pure CBD Isolate out of Hong Kong and directly to the rest of the world. Together with a vast distribution network and custom product and branded formulations via Northern Vine Labs, Vergence aims to promote healthy living through natural remedies. Vergence is in possession of over 100 Natural Product Numbers (NPN's) as granted by Health Canada and plans to develop and distribute these products into global markets for end use.

Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte analysts, driven by the legalization of recreational cannabis next year. While many licensed producers are focused on expanding capacity, the best opportunities may be those that can add value for existing licensed producers. These opportunities include those companies focused on higher value cannabis extracts. Read here why the proprietary extraction technology from Abattis represents an important breakthrough that investors shouldn’t ignore.

Chart source: The Value Case For Investing In The Cannabis Sector
Goldman Small Cap Research report, 'This Stock Set to Double Thanks to New License'
Abattis Bioceuticals Corp. - Stock Up Big on Recent News, Greater Gains on Horizon (October 20, 2016).

Goldman Small Cap Research report 
'The Next Industry-Changing Specialty Health Stock'
Abattis Bioceuticals Corp. - Major Revenue Ahead for Innovative, Diversified Bioceuticals Pioneer (June 13, 2016).

There are an unlimited number of common shares without par value authorized for issue.

Issued & Outstanding (10/08/2017)The Company has 167,580,301 common shares issued and outstanding (source)

System for Electronic Document Analysis and Retrieval (SEDAR) -


Abattis Bioceuticals Corporation
Address: 104 - 9295 198th Street | Langley, BC V1M 3J9 | Canada

As an investor, you are our partner and we take this relationship seriously.
Please contact us if you have any questions or if you would like to invest in Abattis

Brook Bellian | Corporate Communications (778) 883.7869 |


Abattis Bioceuticals
Phone: (604) 336.0881

Northern Vine
(604) 336.0881 | (604) 371.3371 | (604) 888.1129

CHINA | Dr. Shuang Xie  Ph. D.
Suzhou Raybot Material Tech Ltd
T: 17785884380 | C: 17783175968
Phone: 86 5125240581 | 8613901388668
Address:  No. 10-1 Yang Yuan Road,
Xinzhuang Zhen,Changshu | China


22/12/2017 | Abattis Announced its Intent to Purchase Green Tree Therapeutics
18/12/2017 | Abattis Abattis Announces Expansion of Northern Vine Dealer’s License
12/12/2017 | Abattis Confirms Breakthrough Extraction Technology Capabilities
12/12/2017 | Abattis Successfully Closes Private Placement
11/06/2017 | Abattis Validates Lab Strategy, Sets Stage for Rapid Growth
11/01/2017 | Emerald Health Expands Capabilities with Northern Vine Labs Deal
10/26/2017 | Abattis Partnership with Emerald Health Therapeutics
10/19/2017 | Abattis Announces Private Placement
10/04/2017 | Abattis Strikes South Korea Distribution
09/20/2017 | Abattis Prepares for Growth in Extracts
09/15/2017 | Share Swap – Abattis Regain 100% Control Over Northern Vine
09/13/2017 | Important Update on Northern Vine and Sales Division
08/28/2017 | Breakthrough CBD-Based Sunscreen Formulation
08/23/2017 | Northern Vine Provides Update on Growth Targets
08/21/2017 | EXPERION Becoming Legal Cannabis Producer
08/11/2017 | Abattis Adds New Product Line to Subsidiary Vergence
08/09/2017 | Abattis Files Amended and Restated Financial Statements
07/25/2017 | Abattis Expands Its Asian Distribution Sales Channels
07/17/2017 | Abattis Obtains DTC Eligibility
07/15/2017 | Abattis Partners with the CSE & Stockpools
06/15/2017 | New Key Executive and Management Positions
06/13/2017 | Abattis Provides Company Update
06/07/2017 | Abattis Announces New Board Members
05/10/2017 | Northern Vine Labs Expands Its Sales Team
05/03/2017 | Official Launch of Northern Vine Laboratory
04/26/2017 | Abattis Signed Exclusive Destribution Agreement
04/10/2017 | Abattis Bioceuticals Announces New CEO
04/06/2017 | Abattis Gets Added to the Marijuana Index by MJIC
04/04/2017 | Near-term Legalization Puts Testing into Focus
03/27/2017 | Next Month - Legislation to Legalize Marijuana in CA
03/20/2017 | Dr. David Galvez - New Science Advisor of Northern Vine
03/13/2017 | Abattis Team Positions for Next Stage of Growth
03/07/2017 | LP Highlights Continued Need for Testing
02/24/2017 | Abattis Prepares to Launch Northern Vine Labs
02/24/2017 | Abattis Annual Report - September 30, 2016
02/14/2017 | Abattis Audit Update
02/08/2017 | Key Shortcomings in Canada's Cannabis Industry
02/03/2017 | Abattis Audit Update
12/16/2016 | Abattis Provides Corporate Update
12/09/2016 | $ 5 Million Facility with Aluminia Partners
11/15/2016 | Dr. Shuang Xie – Director and CTA
11/09/2016 | Licensing Deal and Brand Acouisition
11/07/2016 | Renewal of Health Canada Licence
11/02/2016 | Appointment of New Independent Director
10/24/2016 | Agreement to Acquire 100% of Experion
10/17/2016 | Experion Prepares for Construction
10/05/2016 | MOU with Global Damon Pharma of South Korea
10/03/2016 | Northern Vine Receives Controlled Substance Licence

If you want to add or to change something on this site - send a message to guay.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#31517  Sticky Note Abattis Announces LOI for Partnership with Alliance of GreenBrickRoad 01/09/18 10:05:18 AM
#31025  Sticky Note Abattis Successfully Closes Private Placement: Goodbuddy4863 12/12/17 07:44:20 PM
#12064  Sticky Note BOARD WARNING - Please Read: IH Admin [Shelly] 06/09/14 01:18:32 PM
#30345   'guay' It's not a matter of chopping & Shaark 09/22/17 11:23:22 AM
#30344   Cannabis R&D Firms See Wild Growth Curve guay 09/22/17 11:14:42 AM
#30343   Hi Shaark – you said ATTBF will probably guay 09/22/17 11:11:58 AM
#30342   'guay' The picture that is painted with these Shaark 09/22/17 10:57:23 AM
#30341   Why Pot Stocks Stumbled guay 09/22/17 10:54:30 AM
#30340   Yes please illume this board with your insight guay 09/22/17 05:10:12 AM
#30339   Yes ... unfortunately I can not keep up guay 09/22/17 04:37:35 AM
#30338   Tip: be realistic and provide neutral not puff StarFishPatrick 09/21/17 11:13:05 PM
#30337   Not sure why you posted this to me StarFishPatrick 09/21/17 11:12:09 PM
#30336   BARCHART 86% Strong Buy! farviewhill 09/21/17 09:19:38 PM
#30335   Some can't see forward. I'm waiting for StormanNorman 09/21/17 09:00:55 PM
#30334   Agree ... and the next wave up - guay 09/21/17 05:05:26 PM
#30333   Abattis is at the mercy of a drastic GreenBrickRoad 09/21/17 02:32:55 PM
#30332   It's going back to the 0.20's. The question GreenBrickRoad 09/21/17 02:26:13 PM
#30331   ... indeed, it takes them a while to guay 09/21/17 02:23:55 PM
#30330   Tip: Invest in a company to which you guay 09/21/17 08:48:08 AM
#30329   Nine months ended June 30, 2017 compared with guay 09/21/17 08:37:22 AM
#30328   1 million shares? Almost 200,000 CAD for these efforts? StarFishPatrick 09/20/17 11:14:40 PM
#30327   I simply can't understand why you wouldn't want StarFishPatrick 09/20/17 11:13:41 PM
#30326   Yeah, I choose not to show huge losses ebota12 09/20/17 05:52:12 PM
#30325   Choices speak louder than words and you still dangerx 09/20/17 05:14:09 PM
#30324   worth reading – Cannabis Lab Testing Is The guay 09/20/17 04:49:37 PM
#30323   Abattis Prepares for Growth in Extracts guay 09/20/17 03:40:37 PM
#30322   Because unfortunately I've been here a long time. ebota12 09/20/17 01:14:49 PM
#30321   @ebota12 why so much hate? Mr Hand 09/20/17 01:00:45 PM
#30320   This is precisely the bullshit that frustrates long ebota12 09/20/17 11:10:56 AM
#30319   Just got this Mr Hand 09/20/17 10:35:40 AM
#30318   Is Abattis at 200 Mil O/S yet? GreenBrickRoad 09/20/17 10:33:23 AM
#30317   I don't enjoy seeing dilution and shares being GreenBrickRoad 09/20/17 10:32:16 AM
#30316   always the same old story and always harping guay 09/20/17 07:34:28 AM
#30315   Take a look at the goodies they are StarFishPatrick 09/19/17 07:25:23 PM
#30314   Abattis is in the most reliable and best farviewhill 09/19/17 06:16:14 PM
#30313   Welcome to Dumpsville. Population: US ebota12 09/19/17 02:53:58 PM
#30312   I share your very bullish assessment. farviewhill 09/18/17 10:17:31 PM
#30311   Many will find ATTBF soon enough. July 2018 Penny Masters 09/18/17 07:30:17 PM
#30310   We and others need to do all we farviewhill 09/18/17 04:46:02 PM
#30309   entirely agree ! guay 09/18/17 03:40:42 PM
#30308   License producers need to go through mandated testing farviewhill 09/18/17 03:19:26 PM
#30307   Either that, or a good time for the ebota12 09/18/17 01:48:31 PM
#30306   I agree. Good decision by management. farviewhill 09/18/17 01:14:25 PM
#30305   @ebota12 #30297 19% of a grow that still Mr Hand 09/18/17 11:54:12 AM
#30304   I do not know how often you have guay 09/18/17 11:34:05 AM
#30303   How many times do I have to be StarFishPatrick 09/17/17 04:51:26 PM
#30302   Bad blood between principals. StarFishPatrick 09/17/17 04:50:26 PM
#30301   Nonsense... "Some marriages work better with separate beds". guay 09/17/17 07:02:48 AM
#30300   I could see why Experion would hate Abattis, ebota12 09/16/17 09:20:12 PM
#30299   I guess we now know that amazing MOU StarFishPatrick 09/16/17 06:51:59 PM
#30298   ATTBF - Lets see 10-20 million traded daily. Penny Masters 09/16/17 10:56:49 AM
#30297   19% of an LP for 25% of a ebota12 09/16/17 09:23:56 AM
#30296   Abattis Bioceuticals Corporation and Morro Bay Resources Ltd. guay 09/16/17 08:20:19 AM